Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Response to: Comment on "New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept".

Miranda-Hernández MP, López-Morales CA, Perdomo-Abúndez FC, Salazar-Flores RD, Ramírez-Ibanez ND, Pérez NO, Molina-Pérez A, Revilla-Beltri J, Medina-Rivero E, Flores-Ortiz LF.

J Immunol Res. 2018 Feb 21;2018:6156024. doi: 10.1155/2018/6156024. eCollection 2018. No abstract available.

2.

Development and validation of a bioassay to evaluate binding of adalimumab to cell membrane-anchored TNFα using flow cytometry detection.

Camacho-Sandoval R, Sosa-Grande EN, González-González E, Tenorio-Calvo A, López-Morales CA, Velasco-Velázquez M, Pavón-Romero L, Pérez-Tapia SM, Medina-Rivero E.

J Pharm Biomed Anal. 2018 Jun 5;155:235-240. doi: 10.1016/j.jpba.2018.03.057. Epub 2018 Mar 30.

3.

Revisiting the False Confession Problem.

Alvarez-Toro V, Lopez-Morales CA.

J Am Acad Psychiatry Law. 2018 Mar;46(1):34-44.

PMID:
29618534
4.

Design of a strong cation exchange methodology for the evaluation of charge heterogeneity in glatiramer acetate.

Campos-García VR, López-Morales CA, Benites-Zaragoza E, Jiménez-Miranda A, Espinosa-de la Garza CE, Herrera-Fernández D, Padilla-Calderón J, Pérez NO, Flores-Ortiz LF, Medina-Rivero E.

J Pharm Biomed Anal. 2017 Jan 5;132:133-140. doi: 10.1016/j.jpba.2016.10.002. Epub 2016 Oct 4.

PMID:
27721069
5.

New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept.

Miranda-Hernández MP, López-Morales CA, Perdomo-Abúndez FC, Salazar-Flores RD, Ramírez-Ibanez ND, Pérez NO, Molina-Pérez A, Revilla-Beltri J, Flores-Ortiz LF, Medina-Rivero E.

J Immunol Res. 2016;2016:9697080. doi: 10.1155/2016/9697080. Epub 2016 Jun 12.

6.

Optimization of a recombinant human growth hormone purification process using quality by design.

Ortiz-Enriquez C, Romero-Díaz AJ, Hernández-Moreno AV, Cueto-Rojas HF, Miranda-Hernández MP, López-Morales CA, Pérez NO, Salazar-Ceballos R, Cruz-García N, Flores-Ortiz LF, Medina-Rivero E.

Prep Biochem Biotechnol. 2016 Nov 16;46(8):815-821.

PMID:
26829467
7.

Pharmacokinetic Comparability of a Biosimilar Trastuzumab Anticipated from Its Physicochemical and Biological Characterization.

Miranda-Hernández MP, López-Morales CA, Piña-Lara N, Perdomo-Abúndez FC, Pérez NO, Revilla-Beltri J, Molina-Pérez A, Estrada-Marín L, Flores-Ortiz LF, Ruiz-Argüelles A, Medina-Rivero E.

Biomed Res Int. 2015;2015:874916. doi: 10.1155/2015/874916. Epub 2015 Nov 19.

8.

Physicochemical and biological characterization of a biosimilar trastuzumab.

López-Morales CA, Miranda-Hernández MP, Juárez-Bayardo LC, Ramírez-Ibáñez ND, Romero-Díaz AJ, Piña-Lara N, Campos-García VR, Pérez NO, Flores-Ortiz LF, Medina-Rivero E.

Biomed Res Int. 2015;2015:427235. doi: 10.1155/2015/427235. Epub 2015 May 17.

9.

Assessment of physicochemical properties of rituximab related to its immunomodulatory activity.

Miranda-Hernández MP, López-Morales CA, Ramírez-Ibáñez ND, Piña-Lara N, Pérez NO, Molina-Pérez A, Revilla-Beltri J, Flores-Ortiz LF, Medina-Rivero E.

J Immunol Res. 2015;2015:910763. doi: 10.1155/2015/910763. Epub 2015 Apr 20.

10.

Validation of three viable-cell counting methods: Manual, semi-automated, and automated.

Cadena-Herrera D, Esparza-De Lara JE, Ramírez-Ibañez ND, López-Morales CA, Pérez NO, Flores-Ortiz LF, Medina-Rivero E.

Biotechnol Rep (Amst). 2015 Apr 18;7:9-16. doi: 10.1016/j.btre.2015.04.004. eCollection 2015 Sep.

Supplemental Content

Loading ...
Support Center